Ibogaine and ketamine are both being used for treatment-resistant depression and PTSD. They are not alternatives to each other. The mechanisms differ, the safety profiles differ, and the populations each medicine serves differ. Choosing between them — or deciding that neither is appropriate — requires understanding what each actually does.
Ibogaine is a polypharmacological compound that acts simultaneously on serotonin, dopamine, opioid, NMDA, and sigma-2 receptors, upregulates the neurotrophic factors GDNF and BDNF, and disrupts the default mode network. A single ceremony produces effects sustained for weeks to months by its metabolite, noribogaine. Ketamine is an NMDA receptor antagonist that produces rapid antidepressant effects — typically within hours — that diminish over days to weeks, requiring ongoing infusions.
How Ibogaine and Ketamine Work Differently
Ketamine's mechanism is focused. It blocks NMDA receptors — glutamate signalling sites in the brain. That blockade triggers a compensatory increase in BDNF and activates mTOR signalling, which promotes new synaptic connections in the prefrontal cortex. This explains ketamine's rapid antidepressant effect, often apparent within 2–4 hours of administration. The effect is real. It is also temporary — the structural changes diminish over days to weeks, which is why clinical protocols require repeated infusions.
Ibogaine acts on many more targets simultaneously. It binds to the serotonin transporter — at a different site than SSRIs — and modulates dopamine, opioid, NMDA, and sigma-2 receptors. It also directly upregulates GDNF (Glial Cell Line-Derived Neurotrophic Factor), a protein that promotes neuron survival and repair. Noribogaine — the compound ibogaine converts to in the body — sustains elevated BDNF for weeks after ibogaine itself has cleared. The metabolite is what gives ibogaine its sustained duration profile.
The third significant mechanism is default mode network disruption. The DMN is the brain's self-referential processing loop — the engine of rumination, negative self-appraisal, and rigid thought patterns that characterise depression and PTSD. Ibogaine disrupts this network during the acute experience. Ketamine produces dissociation; ibogaine produces introspection. These are not the same thing, and the distinction matters for what each medicine can address.
The pharmacological breadth of ibogaine is documented in peer-reviewed literature going back decades. It is part of why researchers have been interested in it — and part of why its safety requirements are more demanding than ketamine's.
What Each Medicine Treats — and Where They Diverge
Depression.Both medicines produce meaningful results in treatment-resistant cases. Ketamine produces antidepressant responses within hours in 50–70% of people who have not responded to standard antidepressants. The response typically diminishes over 2–4 weeks. Ibogaine's antidepressant effects emerge over 24–72 hours post-ceremony and are sustained for months by noribogaine. The 2023 Stanford study published in Nature Medicine found an average 87% reduction in depression symptoms at one month post-treatment — in 30 special operations veterans whose conditions had not responded to conventional approaches. Conventional antidepressant research considers a 50% reduction in depression scores a strong response.
PTSD.The same Stanford study found an average 88% reduction in PTSD symptoms and 81% reduction in anxiety at one month. Ketamine's dissociative state limits its utility for trauma processing — the absence of narrative content means there is less material to work with in integration. Ibogaine's introspective character tends to surface specific experiences and patterns, which makes integration more demanding — and more applicable to trauma.
Opioid addiction. This is where the two medicines diverge most clearly. Ketamine has no established clinical role in treating opioid dependence. Ibogaine acts directly on opioid receptors and has been observed to interrupt withdrawal and reduce craving within hours of a single ceremony — in a way that nothing else approaches. People who enter an ibogaine ceremony in active opioid withdrawal typically emerge from the acute experience with dramatically reduced or absent physical withdrawal symptoms.
The people who show the strongest responses to ibogaine are often those who have already tried everything else — including, in some cases, ketamine infusions that produced two weeks of relief before requiring maintenance they could not sustain. They arrive not with optimism but with evidence that partial responses are not enough. That distinction — between hoping something will work and being ready for what it actually involves — tends to matter.
Duration and What Ongoing Treatment Means
A ketamine infusion in a clinical setting takes approximately 40 minutes intravenously. Standard initial protocols use six infusions over 2–3 weeks. Maintenance infusions follow every 2–4 weeks to sustain the antidepressant effect. This is a description of how ketamine works, not a criticism of it. For some people, ongoing maintenance at manageable cost is a workable structure. For others, it is not.
An ibogaine ceremony runs 12–24 hours of active experience. Recovery takes 2–3 days on-site. Noribogaine — the active metabolite — remains biologically present for weeks to months and sustains the neuroplasticity changes initiated during the acute phase. What is done during that window determines whether lasting change is possible.
This is not a reason to prefer ibogaine. It is a reason to understand what it asks of you. The ceremony opens a period during which new patterns are more accessible and old patterns more malleable. The window does not stay open indefinitely. Integration support during this period — structured, deliberate, and sustained — is not an optional supplement. It is the mechanism by which lasting change becomes possible.
Providers who complete the ceremony, hand someone a pamphlet, and send them home are not providing ibogaine treatment. They are providing ibogaine.
What Medical Screening Involves for Ibogaine
Ketamine has a relatively low baseline medical risk profile for most people. Contraindications exist — uncontrolled hypertension, active psychosis, certain medications — but the screening requirements are not intensive by comparison.
Ibogaine prolongs the QT interval — a measure of the heart's electrical cycle — and in people with pre-existing cardiac conditions, this can produce fatal arrhythmia. EKG is not a formality. It is the mechanism by which people with contraindicated cardiac profiles are identified before ceremony, not during it. The fatalities associated with ibogaine are concentrated among providers who did not conduct this screening.
Medical screening required for every participant at ExploreBwiti:
- Full medical history review
- EKG and cardiovascular assessment
- Blood panel — liver function, kidney function, complete blood count
- Review of all current medications
- Psychiatric history assessment
Ibogaine is metabolised by the liver. Severe liver disease is an absolute contraindication. SSRIs and SNRIs are absolute contraindications due to the risk of serotonin syndrome. If you are currently on antidepressants, a supervised taper with the prescribing physician is required before ceremony is possible. The taper takes weeks to months depending on the medication and dosage. Do not accept any provider who suggests stopping medication a few days before ceremony.
Legality and Cost in Canada
Ketamine is licensed in Canada for anaesthetic use and prescribed off-label for treatment-resistant depression. Clinics operating with physician oversight are legal. Spravato (esketamine nasal spray) is available in some Canadian jurisdictions under physician supervision.
Ibogaine is not listed under Canada's Controlled Drugs and Substances Act. It is not approved for medical use. It is not explicitly prohibited — a meaningfully different legal position from the United States, where it is Schedule I, or the United Kingdom, where it is Class A. A small number of providers operate legally in British Columbia. Following the 2023 Stanford results, Texas committed $50 million USD to clinical ibogaine trials at UTMB, UTHealth Houston, Texas A&M University, and Baylor University. Registered trials are accumulating. Oregon has enacted legislation permitting regulated medical ibogaine.
At ExploreBwiti in Vancouver, ibogaine ceremony costs $2,000–$5,000 CAD — a single all-inclusive fee covering the on-site medical professional present throughout the full 12–24 hours of active ceremony, the medicine, and facilitation. Integration coaching is available at $150–$300 CAD per session. Initial ketamine infusion protocols typically run $2,400–$4,800 USD for six sessions, with maintenance infusions every 2–4 weeks thereafter. Over five years, ketamine maintenance substantially exceeds the cost of a single ibogaine programme — not an argument for ibogaine, but part of the honest comparison.
Who This Is Not For
The following are absolute contraindications for ibogaine — not risk factors to weigh, but conditions that make ibogaine unsafe regardless of circumstances or motivation:
- QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction
- Current SSRIs or SNRIs — without a completed supervised taper first
- Methadone — without a specific supervised transition protocol
- Lithium or certain other psychiatric medications with cardiac effects
- Severe liver or kidney disease
- Active psychosis or schizophrenia spectrum disorder
- Pregnancy
Beyond the absolute medical contraindications, ibogaine ceremony is not appropriate for someone in acute psychiatric crisis — regardless of how badly they want it. The experience amplifies what is present. Entering it in a state of acute instability does not produce stability. The conversation that ends in "this is not the right path for you at this moment" is one of the most important things a provider does. It is also the most uncomfortable to have. We say it directly, and without softening it.
If ketamine is available to you, tolerated, and producing meaningful benefit — even partial benefit requiring maintenance — that is not a reason to stop and pursue ibogaine instead. Ibogaine is not automatically better. It requires more preparation, carries more medical risk, and demands more from the person in the aftermath. The question is not which medicine is superior in the abstract. It is which medicine is appropriate given what you are dealing with, what your medical history shows, and what you are able to do with the aftermath.
People primarily seeking a profound experience or a shortcut to insight are not appropriate candidates for ibogaine. The medicine does not accommodate that framing. It tends to deliver what is needed rather than what is wanted, and those are consistently not the same thing.
Is This Right for You?
The first step is a screening conversation, not a commitment. At ExploreBwiti in Vancouver, every application is reviewed personally within 2–3 business days. If ibogaine is not appropriate at this time, we say so — directly and without softening it. We would rather lose a potential participant than put someone at risk.
For what ibogaine ceremony involves in full, the ceremony page covers the structure of what we offer in Vancouver, BC. The FAQ addresses the most common questions about screening, preparation, and what to expect. If you are ready to begin the conversation, the application takes about ten minutes.
Post-ceremony support is covered on the integration page. The neuroplasticity window that noribogaine opens is finite — what is done during it determines the outcome. For background on the Stanford data, the Stanford ibogaine study post covers what the research found and what it does not claim. The full landscape of current registered ibogaine clinical trials is accessible on ClinicalTrials.gov.